Entries by LRuas

First-in-Human Study: Amplivant® Adjuvant Boosts Immune Response of Synthetic Long Peptide Immunotherapy

/in

First-in-human study investigating the safety and immunogenicity of ISA’s proprietary Amplivant adjuvant conjugated to human papillomavirus type 16 (HPV16) Synthetic Long Peptides (SLPs). SLPs conjugated to Amplivant elicit a significant, strong immune response and dose related systemic T cell immunity when injected intradermally. Study demonstrates that SLPs conjugated to Amplivant have highly favourable tolerability and […]

Can private markets continue to drive development in Life Sciences? – Insights from Optimum’s Healthcare Conference

/in ,

We were proud to host a fantastic panel chaired by BioCentury’s European Editor Stephen Hansen with Soren Moller, Managing Partner of Novo Seeds; Karin Kleinhans, Partner of MRL Ventures Fund; Hakan Goker, Managing Director of M Ventures; Roel Bulthuis, Managing Partner at Inkef. This panel of Venture Capital (VC) investors discussed the strength of private […]

CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology

/in

Inobrodib is a pioneering drug targeting twin tumour drivers p300/CBP, providing a new way to treat specific cancers Objective responses have been observed in multiple settings, including as monotherapy in relapsed refractory multiple myeloma ASH is the annual flagship scientific and clinical haematology meeting which is taking place in New Orleans on 9-13 December 2022 […]

Biocomposites to host Infection Management Symposium on new best practice framework for treating diabetic foot infections at Wounds UK

/in

Consensus group of clinicians have developed a framework of best practice and toolkit for podiatrists treating diabetic foot infections STIMULAN placed in foot wounds following debridement can release antibiotics at therapeutic concentrations  Keele, UK, 3 November 2022 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in […]

Novo Holdings acquires KabaFusion from Pritzker Private Capital. KabaFusion’s clinician-led management team will remain significant investors in the business alongside Novo Holdings

/in

Novo Holdings, a leading healthcare investment firm, announced today its acquisition of KabaFusion (the “Company”), a leading national provider of home infusion therapies, from Pritzker Private Capital (“PPC”), a leader in family direct investing. Terms of the transaction were not disclosed. Read more here.

© Optimum Strategic Communications.